The antibiotic sorangicin A inhibits promoter DNA unwinding in a Mycobacterium tuberculosis rifampicin-resistant RNA polymerase

Rifampicin (Rif) is a first-line therapeutic used to treat the infectious disease tuberculosis (TB), which is caused by the pathogen Mycobacterium tuberculosis (Mtb). The emergence of Rif-resistant (Rif(R)) Mtb presents a need for new antibiotics. Rif targets the enzyme RNA polymerase (RNAP). Sorang...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Proc Natl Acad Sci U S A
Päätekijät: Lilic, Mirjana, Chen, James, Boyaci, Hande, Braffman, Nathaniel, Hubin, Elizabeth A., Herrmann, Jennifer, Müller, Rolf, Mooney, Rachel, Landick, Robert, Darst, Seth A., Campbell, Elizabeth A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: National Academy of Sciences 2020
Aiheet:
Biological Sciences
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7720108/
https://ncbi.nlm.nih.gov/pubmed/33199626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.2013706117
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia